Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population
- 1 October 2005
- journal article
- research article
- Published by American Public Health Association in American Journal of Public Health
- Vol. 95 (10) , 1737-1739
- https://doi.org/10.2105/ajph.2004.056150
Abstract
We assessed feasibility and outcome of hepatitis C virus (HCV) treatment in male correctional inmates in British Columbia, Canada. We reviewed the medical charts of 114 treated inmates; 80 had complete data for treatment outcome. Approximately 4 of 5 inmates completed treatment (78.8%); 66.3% achieved sustained virological response. Those who completed treatment, those with injection drug use as a risk factor, and those with genotypes 2 and 3 were significantly more likely to achieve sustained virological response. HCV treatment in correctional inmates is feasible and effective.Keywords
This publication has 15 references indexed in Scilit:
- Impact of Adherence on the Outcome of Antiviral Therapy for Chronic Hepatitis CJournal of Clinical Gastroenterology, 2005
- Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of CanadaJournal of Urban Health, 2004
- Treatment of Chronic Hepatitis C Virus in the Virginia Department of Corrections: Can Compliance Overcome Racial Differences to Response?American Journal of Gastroenterology, 2004
- HIV and Hepatitis C Virus Testing and Seropositivity Rates in Canadian Federal Penitentiaries: A Critical Opportunity for Care and PreventionCanadian Journal of Infectious Diseases and Medical Microbiology, 2004
- Prior opiate injection and incarceration history predict injection drug use among inmatesAddiction, 2003
- Treatment of Chronic Hepatitis C in a State Correctional FacilityAnnals of Internal Medicine, 2003
- Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?New England Journal of Medicine, 2001
- Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter studyGastroenterology, 2001
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusPublished by Elsevier ,1998
- Management of Viral Hepatitis: Clinical and Public Health Perspectives – A Consensus StatementCanadian Journal of Gastroenterology and Hepatology, 1997